21-385 Phase I
A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS (View details on clinicaltrial.gov)
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
A PHASE 1 STUDY OF TJ033721 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS (View details on clinicaltrial.gov)
A Phase 1 Trial of Melphalan, BCNU, Hydroxocobalamin, Ascorbic Acid, and Autologous Bone Marrow Stem Cell Infusion in Patients With Pancreatic Cancer and an Inherited BRCA1 or BRCA2 Mutation (View details on clinicaltrial.gov)
A Phase 1, First-in-Human Study of DCC-3116 as a Single Agent and in Combination with Trametinib in Patients with Advanced or Metastatic Solid Tumors with RAS or RAF Mutations (View details on clinicaltrial.gov)
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (View details on clinicaltrial.gov)
A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a SA and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (View details on clinicaltrial.gov)
A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation (View details on clinicaltrial.gov)
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology (View details on clinicaltrial.gov)
A phase II, open label, randomized, parallel arm study of NIS793 (with or without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) (View details on clinicaltrial.gov)
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer (View details on clinicaltrial.gov)
First in Human Phase 1/2 Trial of ELI-002 Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors (View details on clinicaltrial.gov)